Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's SK Biopharmaceuticals Quietly Sets Its Eyes On The U.S. - And China

This article was originally published in PharmAsia News

Executive Summary

SEOUL - After completion of preclinical trials with Chinese contract research organization Shanghai Medicilon Inc., Korea's SK Biopharmaceuticals Co. said Oct. 18 that it plans to file an Investigational New Drug application to conduct clinical trials in the U.S. - possibly in 2014 - for a compound to treat depression and manic bipolar disorder

You may also be interested in...



Korean Government Steps Up R&D Incentives For Domestic Companies And MNCs

The Korea Drug Development Fund and the Health Ministry are pursuing two separate projects, but targeting the same goal of helping R&D-focused companies.

Korea’s SK Chemicals Looks To Sell First Generic Patch Of Novartis’ Exelon In Europe

SK Chemicals has signed a deal with 12 European pharmaceutical companies to sell its Alzheimer’s patch SID710, which it says, will be the first generic patch of Novartis’ Exelon in Europe.

Korea's Hanwha Chemical Leads With Enbrel Biosimilar - BIO Korea

SEOUL - South Korea's Hanwha Chemical Corp. - a latecomer to the biopharma industry - is trying to carve out a share of the biosimilars market with a version of Amgen's rheumatoid arthritis blockbuster Enbrel (etandercept), which is to be sold by Merck & Co. outside of Korea

Related Content

UsernamePublicRestriction

Register

SC076489

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel